Decitabine improves patient outcomes in myelodysplastic syndromes

@article{Kantarjian2006DecitabineIP,
  title={Decitabine improves patient outcomes in myelodysplastic syndromes},
  author={H. Kantarjian and J. Issa and C. Rosenfeld and J. Bennett and M. Albitar and J. DiPersio and V. Klimek and J. Slack and C. de Castro and F. Ravandi and R. Helmer and L. Shen and S. Nimer and R. Leavitt and A. Raza and H. Saba},
  journal={Cancer},
  year={2006},
  volume={106}
}
  • H. Kantarjian, J. Issa, +13 authors H. Saba
  • Published 2006
  • Medicine
  • Cancer
  • BACKGROUND Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. [...] Key Method Response was assessed using the International Working Group criteria and required that response criteria be met for at least 8 weeks. Expand Abstract

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Primary: To determine the maximum tolerated dose and schedule of decitabine when administered as maintenance therapy after allogeneic hematopoietic stem cell transplantation… Expand
    ConditionsLeukemia, Myeloid, Acute, Myelodysplastic Syndromes
    InterventionDrug
    Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome
    • 3
    Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
    • 169
    Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
    • 64
    • Highly Influenced
    Myelodysplastic syndromes: 2014 update on diagnosis, risk‐stratification, and management
    • 106
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 32 REFERENCES